SCHEMBL4133407

SCHEMBL4133407

Cc1cc(-c2ccc3c(c2)CCC(N2CCCC2)C3)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
HTR1D P28221 2/20 0.39
DAPK3 O43293 1/20 0.39
NTRK1 P04629 1/20 0.39
PIM1 P11309 1/20 0.39
FLT3 P36888 1/20 0.39
GSK3B P49841 1/20 0.39
ROCK1 Q13464 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
GRIN2B Q13224 7/20 0.37
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GRIN1 Q05586 1/20 0.35
KCNH2 Q12809 1/20 0.35
FAAH O00519 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130877 0.88 HTR1A (0.46) HTR1AHTR7HTR1DGRIN2BDRD2
SCHEMBL4137087 0.88 HTR1D (0.41) HTR1AHTR7HTR1DGRIN2BCYP1A2
SCHEMBL4130376 0.85 HTR1A (0.43) HTR1AHTR7HTR1DGRIN2BDRD2
SCHEMBL4148545 0.84 HTR1A (0.44) HTR1AHTR7HTR1DGRIN2BDRD2
SCHEMBL4140976 0.83 MCHR1 (0.36) DAPK3NTRK1PIM1FLT3GSK3B
SCHEMBL4136016 0.83 HTR1D (0.41) HTR1AHTR7HTR1DGRIN2BCYP1A2
SCHEMBL4142775 0.82 PDE7A (0.42) HTR1DDRD2FAAH
SCHEMBL4149129 0.82 HTR1D (0.38) HTR1AHTR7HTR1DGRIN2BCYP1A2
SCHEMBL4136479 0.81 NAAA (0.51) HTR1AHTR7FAAH
SCHEMBL4141070 0.81 HTR1A (0.41) HTR1AHTR7HTR1DGRIN2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 HTR1A 19/4885HTR7 7/4885HTR1D 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.